Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1988-07-12
1989-12-12
Schain, Howard E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
424101, 514 21, 530380, 530389, 530391, 530406, 530410, 530807, 530828, 530394, 530392, 436529, A61K 3714, A61K 39385, A61K 3702, C07K 1514
Patent
active
048867802
ABSTRACT:
Conjugates of transferrin or ceruloplasmin with anti-tumor agents. Such conjugates are useful in the treatment of tumors. Suitable anti-tumor agents include adriamycin, daunomycin, methotrexate, vincristin, 6-mercaptopurine, cytosine arabinoside and cyclophosphamide. Transferrin or ceruloplasmin is preferably coupled to the anti-tumor agent by means of glutaraldehyde.
REFERENCES:
patent: 3939258 (1976-02-01), Niemann
patent: 4046722 (1977-09-01), Rowland
patent: 4174384 (1979-11-01), Ullman et al.
patent: 4256632 (1981-03-01), Levin et al.
patent: 4320109 (1982-03-01), Nakamura et al.
patent: 4332785 (1982-05-01), Allen et al.
patent: 4376765 (1983-03-01), Trouet et al.
patent: 4378428 (1983-03-01), Farina et al.
patent: 4434156 (1984-02-01), Trowbridge
patent: 4447547 (1984-05-01), Allen et al.
patent: 4448762 (1984-05-01), Richards et al.
patent: 4448763 (1984-05-01), Triplett
patent: 4460561 (1984-07-01), Goldenberg
patent: 4493793 (1985-01-01), Chu
patent: 4522750 (1985-06-01), Ades et al.
patent: 4590001 (1986-05-01), Stjernholm
The Lancet, Aug. 23, 1980, Faulk et al, 390-392.
Makromol. Chem. Suppl. 207-214 (1979), Wilchek.
Nature, 294 (1981), 171-173, Trowbridge et al.
LandOfFree
Conjugates of apotransferrin proteins with anti-tumor agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Conjugates of apotransferrin proteins with anti-tumor agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Conjugates of apotransferrin proteins with anti-tumor agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2121717